Critical Review: Stryker (NYSE:SYK) vs. NAYA Biosciences (NASDAQ:NAYA)

NAYA Biosciences (NASDAQ:NAYA) and Stryker (NYSE:SYK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Earnings & Valuation

This table compares NAYA Biosciences and Stryker”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NAYA Biosciences	$6.23 million	0.14	-$8.03 million	N/A	N/A
Stryker	$22.60 billion	6.31	$2.99 billion	$7.40	50.45

Stryker has higher revenue and earnings than NAYA Biosciences.

Profitability

This table compares NAYA Biosciences and Stryker’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NAYA Biosciences	-119.91%	N/A	-41.72%
Stryker	12.31%	23.74%	11.25%

Volatility & Risk

NAYA Biosciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Institutional & Insider Ownership

12.0% of NAYA Biosciences shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 1.8% of NAYA Biosciences shares are owned by company insiders. Comparatively, 5.2% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for NAYA Biosciences and Stryker, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NAYA Biosciences	0	0	1	0	3.00
Stryker	0	4	15	0	2.79

NAYA Biosciences presently has a consensus price target of $24.00, suggesting a potential upside of 1,732.06%. Stryker has a consensus price target of $427.30, suggesting a potential upside of 14.45%. Given NAYA Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe NAYA Biosciences is more favorable than Stryker.

Summary

Stryker beats NAYA Biosciences on 9 of the 12 factors compared between the two stocks.

About NAYA Biosciences

NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases and fertility. NAYA Biosciences, formerly known as INVO BIOSCIENCE, is based in SARASOTA, Fla.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.